S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

FibroGen Stock Forecast, Price & News

+0.33 (+2.45%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
3.80 million shs
Average Volume
1.12 million shs
Market Capitalization
$1.28 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FibroGen logo

About FibroGen

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.


Does FibroGen (NASDAQ:FGEN) Have A Healthy Balance Sheet?
January 1, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$176.32 million
Book Value
$4.85 per share


Net Income
$-189.29 million
Pretax Margin




Free Float
Market Cap
$1.28 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.81 out of 5 stars

Medical Sector

840th out of 1,418 stocks

Pharmaceutical Preparations Industry

403rd out of 684 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

Is FibroGen a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FibroGen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View analyst ratings for FibroGen
or view top-rated stocks.

How has FibroGen's stock price been impacted by Coronavirus?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FGEN shares have decreased by 61.0% and is now trading at $13.82.
View which stocks have been most impacted by COVID-19

Are investors shorting FibroGen?

FibroGen saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 3,860,000 shares, a decrease of 35.3% from the December 15th total of 5,970,000 shares. Based on an average trading volume of 1,150,000 shares, the days-to-cover ratio is presently 3.4 days. Approximately 4.5% of the company's stock are short sold.
View FibroGen's Short Interest

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for FibroGen

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) announced its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.54 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.09 by $0.45. The biopharmaceutical company earned $155.97 million during the quarter, compared to the consensus estimate of $135.33 million. FibroGen had a negative net margin of 75.62% and a negative trailing twelve-month return on equity of 58.92%. During the same quarter last year, the firm posted $0.35 EPS.
View FibroGen's earnings history

What price target have analysts set for FGEN?

10 Wall Street analysts have issued 1 year target prices for FibroGen's shares. Their forecasts range from $11.00 to $58.00. On average, they anticipate FibroGen's share price to reach $29.50 in the next twelve months. This suggests a possible upside of 113.5% from the stock's current price.
View analysts' price targets for FibroGen
or view top-rated stocks among Wall Street analysts.

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Enrique A. Conterno, Chief Executive Officer & Director
  • Juan Graham, Chief Financial Officer
  • Michael Martinelli, Senior Vice President-Technical Development
  • Elias Kouchakji, Senior VP-Clinical Development & Drug Safety
  • Mark Eisner, Chief Medical Officer

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.16%), Institute for Wealth Management LLC. (0.02%), Newbridge Financial Services Group Inc. (0.02%), Kestra Advisory Services LLC (0.01%) and Cutler Group LP (0.00%). Company insiders that own FibroGen stock include Christine Chung, Enrique A Conterno, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends for FibroGen

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Kestra Advisory Services LLC, and Cutler Group LP. Company insiders that have sold FibroGen company stock in the last year include Kalevi Kurkijarvi, Pat Cotroneo, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen
or view top insider-selling stocks.

Which institutional investors are buying FibroGen stock?

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Newbridge Financial Services Group Inc., and Institute for Wealth Management LLC.. Company insiders that have bought FibroGen stock in the last two years include Enrique A Conterno, and Thane Wettig.
View insider buying and selling activity for FibroGen
or or view top insider-buying stocks.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $13.82.

How much money does FibroGen make?

FibroGen has a market capitalization of $1.28 billion and generates $176.32 million in revenue each year. The biopharmaceutical company earns $-189.29 million in net income (profit) each year or ($2.33) on an earnings per share basis.

How many employees does FibroGen have?

FibroGen employs 599 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

Where are FibroGen's headquarters?

FibroGen is headquartered at 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at [email protected], or via fax at 415-978-1902.

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.